HS
HighVista Strategies Portfolio holdings
AUM
$272M
This Quarter Return
+14.9%
1 Year Return
+24.34%
3 Year Return
+176.43%
5 Year Return
+271.23%
10 Year Return
+682.63%
AUM
$272M
AUM Growth
+$272M
(+4.9%)
Cap. Flow
-$12.8M
Cap. Flow
% of AUM
-4.69%
Top 10 Holdings %
Top 10 Hldgs %
27.33%
Holding
177
New
29
Increased
50
Reduced
55
Closed
31
Top Buys
| 1 |
Viridian Therapeutics
VRDN
|
$4.25M |
| 2 |
Advanced Micro Devices
AMD
|
$2.19M |
| 3 |
Celldex Therapeutics
CLDX
|
$2.17M |
| 4 |
Ferguson
FERG
|
$2.15M |
| 5 |
Mineralys Therapeutics
MLYS
|
$2.03M |
Top Sells
| 1 |
Albertsons Companies
ACI
|
$4.15M |
| 2 |
GE Vernova
GEV
|
$3.07M |
| 3 |
SWTX
SpringWorks Therapeutics
SWTX
|
$3.03M |
| 4 |
Alphabet (Google) Class C
GOOG
|
$2.1M |
| 5 |
Bausch Health
BHC
|
$2.03M |
Sector Composition
| 1 | Healthcare | 37.62% |
| 2 | Technology | 22.09% |
| 3 | Industrials | 8.52% |
| 4 | Financials | 6.08% |
| 5 | Consumer Discretionary | 5.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Axsome Therapeutics
AXSM
$6.05B
| $1.14M | 0.42% | 10,909 -10,594 | -49% | -$1.11M |
|
102
Shift4
FOUR
$6.21B
| $1.12M | 0.41% | +11,300 | New | +$1.12M |
|
103
Scholar Rock
SRRK
$3.14B
| $1.11M | 0.41% | 31,230 | – | – |
|
104
LKQ Corp
LKQ
$8.39B
| $1.09M | 0.4% | 29,500 -7,200 | -20% | -$266K |
|
105
Vaxcyte
PCVX
$4B
| $1.09M | 0.4% | 33,457 +355 | +1% | +$11.5K |
|
106
Soleno Therapeutics
SLNO
$3.6B
| $1.08M | 0.4% | 12,941 -1,403 | -10% | -$118K |
|
107
HDFC Bank
HDB
$182B
| $1.02M | 0.37% | 13,241 -5,000 | -27% | -$383K |
|
108
HubSpot
HUBS
$25.5B
| $1M | 0.37% | 1,800 | – | – |
|
109
MoonLake Immunotherapeutics
MLTX
$3.54B
| $989K | 0.36% | 20,953 -22,588 | -52% | -$1.07M |
|
110
ICICI Bank
IBN
$113B
| $977K | 0.36% | 29,047 -9,700 | -25% | -$326K |
|
111
Vera Therapeutics
VERA
$1.38B
| $954K | 0.35% | 40,473 -11,724 | -22% | -$276K |
|
112
Autoliv
ALV
$9.53B
| $951K | 0.35% | +8,500 | New | +$951K |
|
113
Edgewise Therapeutics
EWTX
$1.51B
| $914K | 0.34% | 69,723 -21,484 | -24% | -$282K |
|
114
Ocular Therapeutix
OCUL
$2.12B
| $825K | 0.3% | 88,876 +3,635 | +4% | +$33.7K |
|
115
Keros Therapeutics
KROS
$618M
| $702K | 0.26% | 52,618 +511 | +1% | +$6.82K |
|
116
Madrigal Pharmaceuticals
MDGL
$9.76B
| $698K | 0.26% | 2,305 +94 | +4% | +$28.4K |
|
117
Roivant Sciences
ROIV
$8.15B
| $690K | 0.25% | 61,268 -54,058 | -47% | -$609K |
|
118
Natera
NTRA
$23.1B
| $678K | 0.25% | 4,014 +164 | +4% | +$27.7K |
|
119
GH Research
GHRS
$837M
| $637K | 0.23% | +52,247 | New | +$637K |
|
120
JD.com
JD
$44.1B
| $626K | 0.23% | 19,183 +8,000 | +72% | +$261K |
|
121
Kanzhun
BZ
$10.8B
| $560K | 0.21% | 31,400 +19,500 | +164% | +$348K |
|
|
CNTA
122
Centessa Pharmaceuticals
CNTA
$2.25B
| $535K | 0.2% | 40,684 +1,664 | +4% | +$21.9K |
|
123
Evolus
EOLS
$494M
| $535K | 0.2% | +58,042 | New | +$535K |
|
124
Corbus Pharmaceuticals
CRBP
$115M
| $520K | 0.19% | 75,292 | – | – |
|
125
Relay Therapeutics
RLAY
$619M
| $518K | 0.19% | +149,701 | New | +$518K |
|